Drug firm Suven Life Sciences today said it has received four product patents in different international markets for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders.
"The four product patents, one from Japan, one from Australia, one from Europe and one from Eurasia...Are valid through 2024 and 2027," Suven Life Sciences said in a filing to the Bombay Stock Exchange (BSE).
The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinson, Alzheimer's disease and Schizophrenia, it added.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally," Suven CEO Venkat Jasti said.
Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II, the company said.
With these new patents, the company now has a total of five patents from Japan, fourteen from Australia, twelve from Europe and ten from Eurasia, it added.
Scrips of Suven Life Sciences were today trading at Rs 15.15 apiece in the afternoon trade on BSE, up 2.02% from its previous close.